Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million. This round included existing investors Connecticut Innovation, HighCape Capital, Advantage Capital (Ironwood) and the National Brain Tumor Society, while also adding new investors Pathway BioVentures, The Sontag Foundation, and BrightEdge, the impact investment and innovation arm of the American Cancer Society.